Neurology News and Research

Latest Neurology News and Research

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.

7 Jun 2010

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

7 Jun 2010

Grifols to acquire Talecris Biotherapeutics

Grifols a global healthcare company and leading producer of plasma protein therapies, and Talecris a U.S.-based biotherapeutics products company, today announced that they have signed a definitive agreement through which Grifols will acquire Talecris for a combination of cash and newly-issued Grifols non-voting shares having an aggregate value today of approximately $3.4 billion (euro 2.8 billion), creating a global leader of life-saving and life enhancing plasma protein therapeutics.

7 Jun 2010

NewYork-Presbyterian Hospital recognized as leader in all 10 clinical specialties

NewYork-Presbyterian Hospital is the only tri-state-area hospital listed on the 2010 U.S.News & World Report "America's Best Children's Hospitals" "Honor Roll" and one of only eight children's hospitals in the nation to be ranked in all 10 clinical specialties. NewYork-Presbyterian provides children's health services at two major centers: NewYork-Presbyterian/Morgan Stanley Children's Hospital and the Phyllis and David Komansky Center for Children's Health.

5 Jun 2010

High frequency ventilation for preterm babies just as effective

A University of Sydney study of ventilation strategies has shown that high-frequency oscillatory ventilation (HFOV) for preterm babies gives the same outcomes as conventional ventilation (CV).

4 Jun 2010

Boehringer Ingelheim to present new data on BIBW 2992 for NSCLC and head-and-neck cancer at ASCO 2010

Boehringer Ingelheim will present promising new data on non-small cell lung cancer as well as head-and-neck cancer for its leading investigational compound BIBW 2992 at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, June 4-8, 2010.

4 Jun 2010

Researchers compare outcomes of two surgical procedures for stress urinary incontinence

As part of a national clinical trial, UT Southwestern Medical Center researchers found little difference in effectiveness between two popular treatments for one of the most common ailments among American women: stress urinary incontinence.

4 Jun 2010

Study confirms Azilect as a selective MAO-B inhibitor

Teva Neuroscience Inc. today announced the publication of a study demonstrating the selectivity of Azilect® (rasagiline tablets) for inhibition of MAO-B (monoamine oxidase-B) at the maximum approved dose of 1 mg/day. The data was published in the Journal of Clinical Pharmacology OnlineFirst on May 5, 2010.

4 Jun 2010

Multiple sclerosis risk sharing scheme: A costly failure

The multiple sclerosis risk sharing scheme is "a costly failure" and should not be continued, according to researchers on bmj.com today. They argue that the biggest losers are the other NHS patients who would otherwise have benefited from the money spent on the scheme, estimated to be around -50m per year since it was set up in 2002.

4 Jun 2010

Advanced CT scanner allows rapid organ imaging, reduces radiation exposure

UT Southwestern Medical Center is the first site in North Texas to launch the next generation in CT scanners, which allow doctors to image an entire organ in less than a second or track blood flow through the brain or to a tumor - all with less radiation exposure to patients.

3 Jun 2010

U-M researchers one step closer to discovering why certain diseases affect specific organs

Why do some diseases affect only specific organs, leaving others invulnerable? Researchers from the University of Michigan have found neural tissue contains imbalanced levels of proteins, which may explain the brain's susceptibility to a debilitating childhood movement disorder.

3 Jun 2010

Research explains brain's susceptibility to dystonia

3 Jun 2010

FDA accepts Eisai's NDA for rabeprazole sodium extended-release 50 mg

Eisai Inc. (Headquarters: Woodcliff Lake, NJ; Chairman and CEO: Hajime Shimizu), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) today announced that the U.S. Food and Drug Administration has accepted Eisai's New Drug Application for rabeprazole sodium extended-release 50 mg for the healing and maintenance of healing of erosive gastroesophageal reflux disease, and for the treatment of symptomatic GERD.

3 Jun 2010

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

Excess levels of a protein associated with TNF may produce cognitive decline: Studies

Two new studies suggest that excess levels of a protein associated with inflammation, TNF, may produce cognitive decline. TNF regulates both inflammation and brain function. TNF is elevated in the blood in many autoimmune diseases, and in the fluid surrounding the brain in Alzheimer's disease.

2 Jun 2010

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.

2 Jun 2010

UT Southwestern researchers compare TVT and TOT sling procedures for stress urinary incontinence

2 Jun 2010

Mannitol improves effectiveness of HUCBs in neonatal rat models of cerebral palsy

The sugar-alcohol compound mannitol improved the therapeutic effectiveness of human umbilical cord blood cells injected into neonatal rat models of cerebral palsy, reports a new international study led by the University of South Florida. The mannitol opened the blood-brain barrier by temporarily shrinking the tight endothelial cells that make up the barrier.

2 Jun 2010

FDA grants priority review status to Eisai's eribulin NDA

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.

2 Jun 2010

Circumstantial evidence suggests first identified Alzheimer disease patient carried N141I presenilin-2 mutation

Writing the latest pages of an anthropological mystery, scientists propose in this month's Archives of Neurology that it is highly possible that Auguste Deter, the first identified Alzheimer disease patient, carried the N141I presenilin-2 mutation—the same one as in present-day U.S. families descended from German emigrants who settled near the river Volga in Russia.

29 May 2010

Neurology News and Research

Latest Neurology News and Research

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Grifols to acquire Talecris Biotherapeutics

NewYork-Presbyterian Hospital recognized as leader in all 10 clinical specialties

High frequency ventilation for preterm babies just as effective

Boehringer Ingelheim to present new data on BIBW 2992 for NSCLC and head-and-neck cancer at ASCO 2010

Researchers compare outcomes of two surgical procedures for stress urinary incontinence

Study confirms Azilect as a selective MAO-B inhibitor

Multiple sclerosis risk sharing scheme: A costly failure

Advanced CT scanner allows rapid organ imaging, reduces radiation exposure

U-M researchers one step closer to discovering why certain diseases affect specific organs

Research explains brain's susceptibility to dystonia

FDA accepts Eisai's NDA for rabeprazole sodium extended-release 50 mg

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Excess levels of a protein associated with TNF may produce cognitive decline: Studies

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

UT Southwestern researchers compare TVT and TOT sling procedures for stress urinary incontinence

Mannitol improves effectiveness of HUCBs in neonatal rat models of cerebral palsy

FDA grants priority review status to Eisai's eribulin NDA

Circumstantial evidence suggests first identified Alzheimer disease patient carried N141I presenilin-2 mutation

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Neurology News and Research

Latest Neurology News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in